J Korean Ophthalmol Soc.  2009 May;50(5):725-730. 10.3341/jkos.2009.50.5.725.

The Efficacy of Ranibizumab for Choroidal Neovascularization in Age-related Macular Degeneration

• Kang S
• Cho WK
• Roh YJ

• KMID: 2212308
• DOI: http://doi.org/10.3341/jkos.2009.50.5.725

Abstract

PURPOSE: To report 1-year clinical changes in visual acuity (VA) after intravitreal ranibizumab therapy for choroidal neovascularization (CNV) due to age-related macular degeneration (AMD), and to determine differences in treatment effects according to the CNV subtype.
METHODS
Forty six patients (46 eyes) with subfoveal CNV were treated with intravitreal ranibizumab (0.5 mg) injections as needed. Visual acuity, fluorescein angiography, and macular OCT were examined after 12 months. The patients were divided into two groups: Classic CNV and occult CNV. The VA of the two groups was compared 12 months after the initial injections.
RESULTS
The average VA and mean central retinal thickness (CRT) before ranibizumab treatment was 1.011+/-0.408 logMAR and 335.3 microm, respectively, and the VA and mean CRT 12 months after the initial injections was 0.928+/-0.357 logMAR and 246.2 microm, respectively (p=0.042, p<0.001). Out of 46 eyes, 13 eyes (28.3%) had a VA that improved by more than 0.1 logMAR, 33 eyes (71.7%) had VA that changed less than 0.1 logMAR, and 40 eyes (86.6%) had a VA that changed by less than 0.3 logMAR. The VA improved to 0.084 logMAR in classic CNV (18 eyes) and to 0.081 logMAR in occult CNV (28 eyes) after 12 months, though the difference between groups was not significant (p=0.910). CONCLUSIONS: Intravitreal injection of ranibizumab is an effective treatment for patients with subfoveal CNV secondary to AMD to improve or stabilize VA, and the effect of treatment on VA is not significantly different according to the CNV subtype.

Keyword

Age-related macular degeneration; Choroidal neovascularization; Ranibizumab

MeSH Terms

Antibodies, Monoclonal, Humanized
Choroid
Choroidal Neovascularization
Eye
Fluorescein Angiography
Humans
Intravitreal Injections
Macular Degeneration
Retinaldehyde
Visual Acuity
Ranibizumab
Antibodies, Monoclonal, Humanized
Retinaldehyde

Figure

• 

  Figure 1. Change in logarithm of the minimum angle of resolution (logMAR) visual acuity over 12 months of 46 eyes treated with intravitreal injection of ranibizumab for subfoveal choroidal neovascularization in age-related macular degeneration. The change of logMAR visual acuity after intravitreal injection of ranibizumab was statistically significant through 12 months (repeated measure ANOVA, * p<0.05).

• 

  Figure 2. Change in logarithm of the minimum angle of resolution (logMAR) visual acuity over 12 months of 46 eyes treated with intravitreal injection of ranibizumab for classic (n=18) and occult (n=28) subfoveal choroidal neovascularization (CNVM) in age-related macular degeneration. There was no statistically significant difference in the mean change of visual acuity between the two groups (Mann-Whitney test, p=0.910).

Reference

References

1. Klein R, Klein BE, Linton KL. Prevalence of age-related maculopathy. The Beaver Dam Eye Stydy. Ophthalmology. 1992; 99:933–43.

2. Ferris FL, Fine SL, Hyman LA. Age-related macular degeneration and blindness due to neovascular maculopathy. Arch Ophthalmol. 1984; 107:1640–2.

3. Adamis AP, Shima DT. The role of vascular endothelial growth factor in ocular health and disease. Retina. 2005; 25:111–8.

4. Ng EW, Adamis AP. Targeting angiogenesis, the underlying disorder in neovascular age-related macular degeneration. Can J Ophthalmol. 2005; 40:352–68.

5. Kaiser PK, Brown DM, Zhang K, et al. Ranibizumab for predominantly classic neovascular age-related macular degeneration: subgroup analysis of first-year ANCHOR results. Am J Ophthalmol. 2007; 144:850–7.

6. Gragoudas ES, Adamis AP, Cunningham ET, et al. Pegaptanib for neovascular age-related macular degeneration. N Engl J Med. 2004; 351:2805–16.

7. Cleary CA, Jungkim S, Ravikumar K, et al. Intravitreal bevacizumab in the treatment of neovascular age-related macular degeneration, 6 and 9 month results. Eye. 2008; 22:82–6.

8. Ferrara N, Damica L, Shams N, et al. Development of ranibizumab, an antivascular endothelial growth factor antigen binding fragment, as therapy for neovascular age-related macular degeneration. Retina. 2006; 26:859–70.

9. Rosenfeld PJ, Brown DM, Heier JS, et al. Ranibizumab for neovascular age-related macular degeneration. N Eng J Med. 2006; 355:1419–31.

10. Brown DM, Kaiser PK, Michels M, et al. Ranibizumab versus verteporfin for neovascular age-related macular degeneration. N Eng J Med. 2006; 355:1432–44.

11. Fung AE, Lalwani GA, Rosenfeld PJ, et al. An optical coherence tomography-guided, variable dosing regimen with intravitreal ranibizumab (Lucentis) for neovascular age-related macular degeneration. Am J Ophthalmol. 2007; 143:566–83.

12. Bashshur ZF, Haddad ZA, Schakal A, et al. Intravitreal bevacizumab for treatment of neovascular age-related macular degeneration: a one-year prospective study. Am J Ophthalmol. 2008; 145:249–56.

13. Hijikata K, Masuda K. Visual prognosis in Behcet's disease: effects of cyclophosphamide and colchicine. Jpn J Ophthalmol. 1978; 22:506–19.

14. Penn JS, Madan A, Caldwell RB, et al. Vascular endothelial growth factor in eye disease. Prog Retina Eye Res. 2008; 27:331–71.

15. Treatment of age-related macular degeneration with photodynamic therapy study group, verteporfin in photodynamic therapy study group. effect of lesion size, visual acuity, and lesion composition on visual acuity change with and without verteporfin therapy for choroidal neovascularization secondary to age-related macular degeneration: TAP and VIP report no. 1. Am J Ophthalmol. 2003; 136:407–18.

16. Treatment of age-related macular degeneration with photodynamic therapy (TAP) study group. Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin: one-year results of 2 randomized clinical trials-TAP report. Arch Ophthalmol. 1999; 117:1329–45.

17. Verteporfin in photodynamic therapy study group. Verteporfin therapy of subfoveal choroidal neovascularization in age-related macular degeneration: two-year results of randomized clinical trial including lesions with occult with no classic choroidal neovascularization-verteporfin in photodynamic therapy report 2. Am J Ophthalmol. 2001; 131:541–60.

18. Lazic R, Gabric N. Verteporfin therapy and intravitreal bevacizumab combined and alone in choroidal neovascularization due to age-related macular degeneration. Ophthalmology. 2007; 114:1179–85.

19. Azad RV, Khan MA, Chanana B, Azad S. Intravitreal bevacizumab for subfoveal choroidal neovascularization secondary to age-related macular degeneration in an Indian population. Jpn J Ophthalmol. 2008; 52:52–6.

20. Boyer DS, Antoszyk AN, Awh CC, et al. Subgroup Analysis of the MARINA Study of Ranibizumab in Neovascular Age-Related Macular Degeneration. Ophthalmology. 2007; 114:246–52.

21. Kaiser PK, Brown DM, Zhang K, et al. Ranibizumab for predominantly classic neovascular age-related macular degeneration: subgroup analysis of first-year ANCHOR results. Am J Ophthalmol. 2007; 144:850–7.